Comparison of Heart Rate Variability Analysis Durations and Their Relationship With Blood Pressure
Condition(s) studied
Investigational drug(s) / intervention(s)
Heart Rate Variability and Blood Pressure Assessment: Participants will complete a single-visit resting physiological assessment under standardized conditions. After an adaptation period, systolic blood pressure, diastolic blood pressure, and pulse will be measured using an automated oscillometric upper-arm blood pressure monitor. Continuous RR interval data will then be recorded using the Polar H10 chest strap and analyzed with Kubios HRV software. Heart rate variability parameters will be calculated from predefined 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous recording for methodological comparison.
Study summary
This observational study aims to compare heart rate variability (HRV) parameters obtained from different analysis durations in healthy adults and to examine how these parameters relate to resting blood pressure values. HRV is a noninvasive measure commonly used to assess autonomic nervous system activity. Standard short-term HRV analysis is typically based on 5-minute recordings, but shorter and longer analysis durations are also used in research and practice. This study will evaluate whether HRV values derived from 1-minute, 5-minute, 10-minute, and 20-minute analysis windows differ from one another and whether their relationships with systolic blood pressure, diastolic blood pressure, and mean arterial pressure change according to analysis duration. Participants will attend a single study visit. After a rest period, resting blood pressure and pulse will be measured, and a continuous HRV recording will be obtained using a chest strap device. The study is designed to provide methodological information on the comparability of different HRV analysis durations under the same physiological conditions.
Eligibility
Primary outcome measure(s)
- RMSSD Across Different Analysis Durations — Baseline, during a single study visit
Root mean square of successive differences (RMSSD), in milliseconds (ms), calculated from predefined 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording obtained under standardized resting conditions. - SDNN Across Different Analysis Durations — Baseline, during a single study visit
Standard deviation of normal-to-normal intervals (SDNN), in milliseconds (ms), calculated from predefined 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording obtained under standardized resting conditions. - Low-Frequency Power Across Different Analysis Durations — Baseline, during a single study visit
Low-frequency (LF) power, in ms\^2, calculated from predefined 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording obtained under standardized resting conditions. - High-Frequency Power Across Different Analysis Durations — Baseline, during a single study visit.
High-frequency (HF) power, in ms\^2, calculated from predefined 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording obtained under standardized resting conditions. - LF/HF Ratio Across Different Analysis Durations — Baseline, during a single study visit.
Low-frequency/high-frequency (LF/HF) ratio calculated from predefined 1-minute, 5-minute, 10-minute, and 20-minute analysis windows extracted from the same continuous resting RR interval recording obtained under standardized resting conditions.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Artvin Coruh University, Artvin Vocational School, Disabled Care and Rehabilitation Laboratory, Artvin, | Artvin | Turkey (Türkiye) |
More Sinop University trials in Turkey
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07531992 on ClinicalTrials.gov ↗ ← All trials in Turkey